Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and share sales in March 2026. She exercised stock options to acquire a total of 44,166 shares of common stock at exercise prices of $6.55 and $7.27 per share, then sold 57,180 shares in open-market transactions.
The sales occurred in three equal blocks of 19,060 shares at weighted average prices of $13.18, $13.37 and $13.83 per share. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 481,906 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported an exercise-and-sell transaction pattern in company stock. Over three days, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $6.55 per share.
She then sold 57,180 shares of common stock in open-market transactions at reported prices of $13.41, $13.40, and $13.18 per share, with each sale executed as multiple trades within disclosed price ranges. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Following these transactions, Rubinstein directly owned 494,920 shares of Adaptive Biotechnologies common stock, indicating she retained a substantial equity position after the option exercises and sales.
Reported registration to sell 18,672 restricted stock units under Rule 144. The filing lists the securities as Restricted Stock Units with an offering/filing date of 03/10/2026. The broker/filing agent is Morgan Stanley Smith Barney LLC.
Separately, the filing discloses prior open-market dispositions by Kyle Piskel: 2,145 shares sold on 02/04/2026 for $39,596.70 and 4,290 shares sold on 01/12/2026 for $77,220.00.
Adaptive Biotechnologies insider filing reports sales. The Form 144 lists 122,523 Restricted Stock Units to be sold with an effective date of 03/10/2026. The filing also details multiple sales by Julie Rubinstein between 03/03/2026 and 03/13/2026, showing individual trade sizes and proceeds.
ADPT filed a Rule 144 notice describing proposed sales of equity awards dated 03/10/2026. The filing lists 140,666 Restricted Stock Units and 329,600 Performance Stock Units to be sold by the issuer through Morgan Stanley Smith Barney LLC.
The filing also reports recent open-market sales by Harlan Robins during Jan–Mar 2026, including multiple transactions such as 14,233 and 10,000 shares on March and January dates.
Chad Robins filed a Form 144 notifying proposed sales of Common Stock in multiple transactions. The notice lists several sales on dates in January–March 2026, including a 03/03/2026 entry for 53,083 shares and multiple entries on 03/02/2026 and 02/27/2026.
The filing lists Restricted Stock Units (140,567) and Performance Stock Units (329,600) with an 03/10/2026 date. The Form 144 records individual share sales with dollar amounts per transaction; cash‑flow treatment and any aggregate total are not provided in the excerpt.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and stock sales. She exercised options to acquire 44,166 shares of common stock at an exercise price of $6.55 per share and sold 179,703 shares in multiple open-market transactions, including sales at $12.63, $12.96, $13.17, $13.43 and $14.08 per share. A portion of the shares sold was mandated to cover tax withholding on RSU vesting, and all transactions were carried out under a Rule 10b5-1 trading plan. After these transactions, she directly holds 507,934 shares of common stock and retains 62,827 fully vested stock options exercisable at $6.55 per share expiring on February 7, 2028.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an open-market sale of 15,394 shares of Common Stock at a weighted-average price of $13.91 per share. The shares were sold in multiple trades between $13.84 and $13.96. After this sale, she directly holds 15,625 shares, meaning her personal stake was significantly reduced but she continues to own stock in the company.